Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMDxHealth SA

MDxHealth SA

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
0.172 USD 0.01 ( 9.55%)
Last update at 2026-11-09T17:46:00Z
VOLUME
572532
Market Cap
75.59M

Momentum Score

…

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.16
Low
0.17
High
52 Week Price Range
2.21
Low
4.64
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

MDxHealth SA is a molecular diagnostics company that develops and commercial tests to improve cancer diagnosis and treatment decisions, with a portfolio centered on non‑invasive urine‑based assays such as SelectMDx for prostate cancer. Long‑term growth drivers include wider clinical adoption of biomarker‑based diagnostics, geographic and indication expansion, and progress on reimbursement and guideline inclusion, which may benefit recurring lab and licensing revenue and help reduce unnecessary procedures for patients. Investors may find the company attractive for its focus on clinically actionable diagnostics and scalable testing model.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.16
Dividend Yield
-
Revenue TTM
75.33M
Revenue Per Share
2.76
Gross Profit TTM
19.22M
Debt / Equity
5.72
ROE
-217.59%
Net Debt
18.89M
ROCE
-34.58%
Diluted EPS TTM
-1.46

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -44.04M -29.00M -28.66M -43.67M -32.49M
Net income -50.19M -30.88M -30.01M -43.10M -32.45M
Selling general administrative 23.54M 5.07M 4.15M 5.68M 6.19M
Selling and marketing expenses 26.58M 2.59M 2.31M 4.43M 9.07M
Gross profit 19.22M 10.41M 7.85M -0.14M 16.69M
Reconciled depreciation 4.91M 3.04M 3.33M 3.42M 2.94M
Ebit -37.90M -26.84M -27.12M -43.17M -32.41M
Ebitda -32.99M -23.90M -23.98M -39.94M -29.47M
Depreciation and amortization 4.91M 2.94M 3.14M 3.23M 2.94M
Operating income -37.90M -26.84M -27.12M -43.17M -32.10M
Other operating expenses 74.95M 49.08M 45.49M 54.95M 60.44M
Interest expense 6.14M 1.88M 1.34M 0.32M 0.08M
Tax provision 0.00M 0.00M 0.00M -0.57M -0.04M
Interest income 0.12M 0.01M 0.00M 0.01M 0.02M
Net interest income -6.14M -1.97M -1.54M -0.50M -0.39M
Income tax expense 6.14M 1.88M 1.34M -0.57M -0.04M
Total revenue 37.05M 22.24M 18.37M 11.79M 28.34M
Total operating expenses 57.12M 37.25M 34.97M 43.02M 48.78M
Cost of revenue 17.84M 11.83M 10.52M 11.93M 11.65M
Total other income expense net -6.14M -2.16M -1.54M -0.51M -0.00M
Net income from continuing ops -44.04M -29.00M -28.66M -43.10M -32.45M
Net income applicable to common shares -44.04M -29.00M -28.66M -43.10M -32.45M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 129.13M 119.14M 75.07M 31.86M 40.63M
Intangible assets 44.34M 46.17M 3.45M 5.06M 7.27M
Other current assets 1.73M 1.96M 0.02M 0.92M 0.00M
Total liab 121.92M 109.82M 28.17M 26.01M 20.90M
Total stockholder equity 7.21M 9.31M 46.90M 5.85M 19.72M
Other current liab 8.59M 6.31M 0.96M 0.91M 0.91M
Common stock 173.93M 133.45M 128.45M 76.72M 62.84M
Capital stock 173.93M 133.45M 128.45M 76.72M 62.84M
Retained earnings -331.45M -288.35M -244.30M -215.30M -186.64M
Other liab - 53.54M 1.47M 0.69M 0.69M
Good will 35.93M 35.93M - - 0.00M
Cash 22.38M 15.50M 58.50M 15.95M 22.05M
Total current liabilities 19.52M 18.28M 16.43M 13.02M 10.43M
Current deferred revenue - - 2.73M 3.22M 3.35M
Net debt 18.89M 24.29M -42.94M -0.08M -11.05M
Short term debt 2.12M 1.79M 5.28M 3.58M 1.22M
Short long term debt 0.64M 0.62M 4.44M 2.82M 0.56M
Short long term debt total 41.27M 39.79M 15.56M 15.87M 11.00M
Other stockholder equity 153.18M 164.65M 163.78M 145.73M 144.44M
Property plant equipment - 7.89M 5.02M 3.71M 2.45M
Total current assets 38.16M 29.15M 66.61M 23.09M 30.91M
Long term investments 0.76M - - - -
Net tangible assets - -72.78M 43.45M 0.79M 12.46M
Short term investments 0.11M - - - -
Net receivables 11.27M 9.36M 5.06M 3.89M 6.70M
Long term debt 35.56M 34.91M 7.65M 10.28M 9.05M
Inventory 2.78M 2.33M 1.91M 2.32M 1.19M
Accounts payable 8.81M 10.18M 7.46M 5.32M 4.96M
Accumulated other comprehensive income 11.55M -0.44M -1.04M -1.30M -0.92M
Non currrent assets other 0.76M - - - -
Non current assets total 90.97M 89.99M 8.47M 8.77M 9.72M
Capital lease obligations 5.06M 4.26M 3.46M 2.77M 1.39M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -29.16M -0.89M -0.54M -0.07M -1.34M
Change to liabilities 3.97M 1.65M 0.23M -2.51M -1.12M
Total cashflows from investing activities -29.16M -1.21M -0.54M -0.07M -1.34M
Net borrowings 22.13M -1.06M 1.49M 8.71M -0.36M
Total cash from financing activities 20.84M 66.50M 14.29M 17.96M 41.67M
Net income -37.90M -26.84M -27.12M -43.17M -32.10M
Change in cash -42.99M 42.55M -6.10M -4.15M 9.38M
Begin period cash flow 58.50M 15.95M 22.05M 26.20M 16.83M
End period cash flow 15.50M 58.50M 15.95M 22.05M 26.20M
Total cash from operating activities -34.12M -22.55M -20.24M -22.29M -28.54M
Issuance of capital stock 0.00M 68.57M 13.88M 9.58M 42.42M
Depreciation 4.91M 3.04M 3.33M 3.42M 2.94M
Other cashflows from investing activities - 0.01M 0.01M 0.01M 0.01M
Dividends paid 0.00M 0.00M 0.00M 0.00M -
Change to inventory -0.42M 0.41M -1.13M 0.61M 0.11M
Change to account receivables -5.12M -1.38M 2.85M 12.19M 0.72M
Other cashflows from financing activities 33.00M -1.01M 0.41M 8.97M -0.39M
Change to netincome 6.58M 3.06M 3.13M 7.10M 1.26M
Capital expenditures 4.16M 0.90M 0.54M 0.07M 1.34M
Change in working capital -1.56M 0.36M 1.95M 10.29M -0.29M
Stock based compensation 0.87M 1.22M 1.29M 0.87M 1.01M
Other non cash items -0.43M -0.33M 0.03M 0.00M -0.10M
Free cash flow -38.28M -23.44M -20.78M -22.36M -29.89M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MDXH
MDxHealth SA		 0.01
9.55%		 0.17 - - 0.90 3.55 1.12 -2.73
TMO
Thermo Fisher Scientific Inc		 12.74
1.83%		 707.50 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.52
1.53%		 233.77 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -0.93
3.65%		 24.52 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 1.01
4.03%		 26.02 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

MDxHealth SA

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

CAP Business Center, Herstal, Belgium, 4040

32 4 257 70 21

https://mdxhealth.com

300

Name Title Year Born
Mr. Michael K. McGarrity CEO & Exec. Director 1963
Mr. Ron Kalfus Chief Financial Officer 1974
Mr. Joseph Sollee Exec. VP of Corp. Devel. & Gen. Counsel 1965
Mr. John A. Bellano Chief Commercial Officer 1969
Ms. Miriam Reyes Exec. VP of Operations 1973
Dr. Wim Van Criekinge Chief Scientific Officer 1972
Mr. Paul Marr Exec. VP of Sales for North America NA
Mr. Michael K. McGarrity CEO & Executive Director 1963
Mr. Joseph Sollee Executive VP of Corporate Development & General Counsel 1965
Ms. Miriam Reyes Executive Vice President of Operations 1973

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +4.22%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.64%

  • Healthcare

    +1.58%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…